The University of Chicago Header Logo

Connection

Kenneth S. Cohen to Benzimidazoles

Back to Details
This is a "connection" page, showing publications Kenneth S. Cohen has written about Benzimidazoles.
Kenneth S. Cohen
Connection Strength
0.135
Benzimidazoles
  1. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
    View in: PubMed
    Score: 0.135
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.